News

A multi-national team of researchers attempting to find precise clinical indicators that would increase post-diagnosis survival times among patients living with systemic scleroderma (SSc), have recently published a study with promising conclusions.  The study consisted of patients previously diagnosed with SSc from the European League Against Rheumatism Scleroderma…

Cytori Therapeutics, Inc announced that the information recently presented in San Francisco regarding the STAR trial, a pivotal clinical trial for scleroderma, is now available on Cytori’s official website. Dr. Dinesh Khanna, Professor of Rheumatology and Associate Professor of Internal Medicine in the Division of Rheumatology and Director of the…

A collaborative group of researchers, based in Australia and China, have found that early screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) using two recently developed methods resulted in identification of PAH in 100% of individuals screened. The study, titled A Comparison of the Predictive Accuracy of Three…

Selexipag (ACT-293987), under development by Actelion, may be able to help individuals affected by “Raynaud’s Phenomenon Secondary to Systemic Sclerosis” in an international phase 2 clinical trial that is currently recruiting participants. The trial, initiated in October 2014, is slated to end in April 2015…

The “STAR” pivotal trial that will test Cytori Cell Therapy as a potential treatment for impaired hand function in scleroderma patients has been granted final approval for its application for an Investigational Device Exemption (IDE). The decision, which was made by a division of the U.S.

A recruiting phase 2 clinical trial sponsored by Dinesh Khanna, MD, MS at the University of Michigan, in collaboration with Bristol-Myers Squibb and National Institute of Allergy and Infectious Diseases (NIAID), is testing the hypothesis “that subcutaneous abatacept is safe and shows evidence of efficacy…

Important to the development of any treatment for scleroderma is a clinical study investigating the pharmacodynamics and pharmacokinetics of a potential drug candidate. NexMed (USA), Inc., a subsidiary of Apricus Biosciences, Inc., is sponsoring a currently enrolling clinical trial investigating these two aspects of alprostadil in systemic sclerosis (SSc)…

A Phase 1 clinical trial recently ended that involved “A Study of the Safety and Tolerability of MEDI-551 in Scleroderma.” MedImmune LLC, sponsor of the study, last updated the results of the trial in an abstract presented through Annals of the…

As patients with scleroderma and Raynaud’s phenomenon know, cold hands can be extremely bothersome and even painful. Fredrick M. Wigley, MD, of Johns Hopkins University led a phase 3 clinical trial in 2014 that evaluated Fasudil, a Rho-kinase inhibitor, for efficacy in preventing vasoconstriction in the fingers and skin,…

“Zibotentan Better Renal Scleroderma Outcome Study (ZEBRA)” is more than a standard clinical trial for scleroderma patients. Rather, the phase 2 clinical trial is a three-part clinical trial seeking to help patients with mild, moderate, or severe kidney disease due to scleroderma. University College, London is…